Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cells for Spinal Cord Injury
NCT05152290Phase 1Recruiting
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
- Start
- Jul 2022
- Primary completion
- Jan 2028
- Modality
- Stem Cell Therapies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial in spinal cord injury (SCI), sponsored by The Foundation for Orthopaedics and Regenerative Medicine. Primary endpoint: Adverse Events at 4 years. Started Jul 2022; status: recruiting.
02
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT05152290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05152290.